The stronger antitumor activity of IBI323 is associated with an increase in tumor-specific CD8+ and CD4+ T cells compared to each parental antibody in PD-L1/LAG-3 double-knocking mice carrying human PD-L1 knocking to MC38 tumors (103). Here, CD274 is linked to neoplasm.